177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Recruiting now · Early Phase 1
Conditions studied: SSTR2 and Integrin αVβ3 Positive Tumors
In brief
Researchers has conducted extensive research on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI, and some researches have revealed 68Ga-TATE-RGD in imaging studies of neuroendocrine tumors to find that the dual-targeted tracer showed an increasing TBR, suggesting the tracer kinetic advantage of TATE-RGD; compared to the single-target tracer DOTATATE, the dual-target TATE-RGD probe has a clear advantage in detecting liver metastases of NETs, and it can be explored for potential therapeutic uses of TATE-RGD in future studies and used for related companion diagnostics in targeted radioisotope therapy (RLT).
Key facts
- Study ID
- NCT06632873
- Run by
- Peking Union Medical College Hospital
- People needed
- 10
- Starts
- 2024-09-01
- Expected to finish
- 2025-02-20
- Last updated by the study team
- 2024-10-15
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients with clear pathological diagnosis and ineffective or progressing clinical conventional treatment;
- tumor lesions with high SSTR2 and RGD untake confirmed on 68Ga-TATE-RGD PET/CT within one week before the injection of 177Lu-TATE-RGD;
- signed written consent.
You may not qualify if…
- the exclusion criteria were a serum creatinine level of more than 150 μmol per liter, a hemoglobin level of less than 10.0 g/dl, a white-cell count of less than 4.0× 109/L, a platelet count of less than 100 × 109/L, a total bilirubin level of more than 3 times the upper limit of the normal range and a serum albumin level of more than 3.0 g per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe allergy or hypersensitivity to radiographic contrast material, claustrophobia;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where it is running
- Chinese Academy of Medical Science & Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.